<DOC>
	<DOC>NCT02366468</DOC>
	<brief_summary>The purpose of this study is to demonstrate that the change of best corrected visual acuity (BCVA) is comparable in patients treated with ranibizumab at the discretion of the investigator vs. treatment according to a standard of care scheme (pro re nata, as needed).</brief_summary>
	<brief_title>Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema</brief_title>
	<detailed_description />
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Vision Disorders</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Patients with Type 1 or Type 2 diabetes mellitus with glycosylated hemoglobin (HbA1c) ≤ 12.0% Patients with visual impairment due to DME in at least one eye BCVA ≥ 24 and ≤ 78 letters in the study eye Active intraocular inflammation Any active infection in either eye at the Structural damage within 0.5 disc diameter of the center of the macula in the study eye Uncontrolled glaucoma in either eye at screening Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Diabetic macular edema</keyword>
	<keyword>Visual impairment</keyword>
</DOC>